drugset / Trial / NCT01043484

Safety and Efficacy Study to Compare Capecitabine + Bevacizumab Versus Capecitabine, Concomitantly With Radiotherapy as Neoadjuvant Treatment for Patients With Localized and Resectable Rectal Cancer

NCT01043484 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the efficacy and safety of the combination of capecitabine + bevacizumab concomitantly with radiotherapy versus capecitabine concomitantly with radiotherapy, as neoadjuvant treatment for patients with localized and resectable rectal cancer.

Timeline

Start
2009-12
Primary completion
2013-01
Completion
2016-08

Outcome

Missed primary endpoint

paper The ypCR rate was 16% in arm A and 11% in arm B (p =0.54). PMID 25886378 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 5 mg/kg —
Background Capecitabine Small molecule 825 mg/m2 —

Indications